Continuing Pharmacy Education / CE Master List / The ABCD of Off-Label Medications for Weight Management-RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

The ABCD of Off-Label Medications for Weight Management-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

1.     Discuss the main principles of management of adiposity-based chronic disease (ABCD)
2.     Identify the efficacy of commonly prescribed medications that may be used off-label for weight reduction
3.     List major safety considerations for medications prescribed off-label for weight reduction

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-038-H01-P

Session Code

23RW38-CBA96

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-038-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Khanh Dang, PharmD, CDCES, FNAP
Clinical Professor
UConn School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Dang has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

Post Test

The ABCD of Off-Label Medications for Weight Management
Post Test
1. When working with a patient to manage ABCD, what is the first goal?

A. prevent weight regain
B. stop further weight gain
C. achieve weight reduction

2. Which of the following is the correct order of weight reduction efficacy (highest to lowest)?

A. tirzepatide > semaglutide > phentermine
B. semaglutide > SGLT2 inhibitors > phentermine
C. metformin = semaglutide > topiramate

3. What did the SELECT RCT report about patients 45 years and older with ABCD and existing cardiovascular disease who did not have diabetes?

A. The placebo-subtracted weight reduction for weekly semaglutide 2.4 mg was 15% of baseline body weight.
B. Subcutaneous semaglutide 2.4 mg once weekly reduced major adverse cardiovascular events in ABCD.
C. Subcutaneous semaglutide 2.4 mg once weekly significantly reduced weight but did not prevent cardiovascular events.

4. What is the most common adverse reaction for GLP-1 receptor agonist-based medications?

A. nausea and other gastrointestinal adverse effects
B. hypoglycemia
C. sleep disturbance

5. With which drug class can tirzepatide interact ?

A. beta blockers
B. ACE inhibitors
C. oral hormonal contraceptives

Handouts

Download

VIDEO